Iranian Society of Gynecology Oncology

Document Type : Original Research Article


Obstetrics and Gynecology Department, Faculty of Medicine, Aswan University, Aswan Governorate, Egypt


Background & Objective: To determine the safety and adequacy of intravenous (IV) carbetocin compared to IV tranexamic acid (TA) plus sublingual misoprostol in reducing hemorrhage during and following cesarean delivery (CD) in women with at least one risk factor for postpartum hemorrhage.
Materials & Methods: This clinical study was randomized. We randomly assigned 400 term pregnant women who were candidates for elective CD to receive either a 100 μg intravenous infusion of carbetocin or 1gm. IV TA along with 400 μg of sublingual misoprostol after delivery. Comparing the quantity of blood loss at and six hours following a CD was the primary result. We also disclosed the necessity for any extra medications and any adverse drug reactions.
Results: When compared to the misoprostol plus tranexamic acid group, the carbetocin group's total mean blood loss was considerably higher (829.7 293.3 mL vs. 609.33 211.5 mL; P = 0.0001). Following the administration of carbetocin and misoprostol with TA, respectively, 9.5% and 26.5% of patients required further uterotonics treatment (P = 0.0001). When compared to the carbetocin group, the misoprostol group's side effects, such as a bad taste in the mouth and fever, were much greater (P = 0.0001).
Conclusion: When it comes to minimizing overall blood loss during and after CD, IV tranexamic acid combined with sublingual misoprostol is superior to IV carbetocin.


 When it comes to minimizing overall blood loss during and after CD, IV tranexamic acid combined with sublingual misoprostol is superior to IV carbetocin.


Main Subjects

1. Chikkamath SB, Katageri GM, Mallapur AA, Vernekar SS, Somannavar MS, Piaggio G, et al. Duration of third stage labour and postpartum blood loss: a secondary analysis of the WHO CHAMPION trial data. Reprod Health. 2021;18(1):1-7. [DOI:10.1186/s12978-021-01284-8] [PMID] [PMCID]
2. Gallos ID, Papadopoulou A, Man R, Athanasopoulos N, Tobias A, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. Cochrane Database Syst Rev. 2018;4(4):CD011689. [DOI:10.1002/14651858.CD011689.pub3] [PMID]
3. Kandil M. The sky rocketing rate of cesarean section in Egypt. Glob Drugs Therap. 2018;3(4):1. [DOI:10.15761/GDT.1000153]
4. Ngwenya S. Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting. Int J Womens Health. 2016;8:647-50. [DOI:10.2147/IJWH.S119232] [PMID] [PMCID]
5. Elbohoty AEH, Mohammed WE, Sweed M, Bahaa Eldin AM, Nabhan A, Abd-El-Maeboud KHI. Randomized controlled trial comparing carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following an elective cesarean delivery. Int J Gynaecol Obstet. 2016;134(3):324-8. [DOI:10.1016/j.ijgo.2016.01.025] [PMID]
6. Oladapo OT, Fawole B, Blum J, Abalos E. Advance misoprostol distribution for preventing and treating postpartum haemorrhage. Cochrane Database Syst Rev. 2012;6(2020):CD009336. [DOI:10.1002/14651858.CD009336.pub3] [PMCID]
7. Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. 2018;2(2):Cd012964. [DOI:10.1002/14651858.CD012964] [PMID] [PMCID]
8. Shady NW, Sallam HF, Elsayed AH, Abdelkader AM, Ali SS, Alanwar A, et al. The effect of prophylactic oral tranexamic acid plus buccal misoprostol on blood loss after vaginal delivery: a randomized controlled trial. J Matern Fetal Neonatal Med. 2019;32(11):1806-12. [DOI:10.1080/14767058.2017.1418316] [PMID]
9. Jagielska I, Kazdepka-Ziemińska A, Kaczorowska A, Madej A, Kolossa T, Grabiec M. Evaluation of carbetocin and oxytocin efficacy in prevention of postpartum hemorrhage in women after cesarean section. Ginekologia Polska. 2015;86(9):689-93. [DOI:10.17772/gp/59023] [PMID]
10. Doctorvaladan SV, Jelks AT, Hsieh EW, Thurer RL, Zakowski MI, Lagrew DC. Accuracy of blood loss measurement during cesarean delivery. Am J Perinatol Rep. 2017;7(02):e93-00. [DOI:10.1055/s-0037-1601382] [PMID] [PMCID]
11. Lilley G, Burkett-st-Laurent D, Precious E, Bruynseels D, Kaye A, Sanders J, et al. Measurement of blood loss during postpartum haemorrhage. Int J Obstet Anesth. 2015;24(1):8-14. [DOI:10.1016/j.ijoa.2014.07.009] [PMID]
12. Mahinthan V, Nicklin A, Tanqueray T. P. 46 Carbetocin vs oxytocin in the prevention of postpartum haemorrhage in caesarean section: A retrospective analysis. Int J Obstet Anesth. 2021;46(1):103044. [DOI:10.1016/j.ijoa.2021.103044]
13. Ugwu IA, Enabor OO, Adeyemi AB, Lawal OO, Oladokun A, Olayemi O. Sublingual misoprostol to decrease blood loss after caesarean delivery: A randomised controlled trial. J Obstet Gynaecol. 2014;34(5):407-11. [DOI:10.3109/01443615.2014.899329] [PMID]
14. Gupta P, Sunita J, Shekhar C. Misoprostol versus oxytocin in prevention of postpartum hemorrhage. J Androl Gynaecol. 2016;4(1):1-4. [DOI:10.13188/2332-3442.1000027]
15. Adanikin AI, Orji E, Adanikin PO, Olaniyan O. Comparative Study of Rectal Misoprostol to Oxytocin Infusion in Preventing Postpartum Haemorrhage After Caesarean Section. J Obstet Gynaecol. 2013;8(2):34-7. [DOI:10.3126/njog.v8i2.9767]
16. Dk U. Impact of Preoperative Rectal Misoprostol on Blood Loss during and after Elective Cesarean Delivery: A Randomized Controlled Trial. Nepal J Obstet Gynaecol. 2016;11(2):37-41. [DOI:10.3126/njog.v11i2.17460]
17. Nayak L, Pradhan K, Mishra S. Role of 400 mcg intraoperative sublingual misoprostol for reduction of caesarean blood loss. J Evid Based Med Healthcare. 2017;4:573-7. [DOI:10.18410/jebmh/2017/112]
18. Musa AO, Ijaiya MdA, Saidu R, Aboyeji AP, Jimoh AA, Adesina KT, et al. Double-blind randomized controlled trial comparing misoprostol and oxytocin for management of the third stage of labor in a Nigerian hospital. Int J Gynaecol Obstet. 2015;129(3):227-30. [DOI:10.1016/j.ijgo.2015.01.008] [PMID]
19. Patil NB, Patted SS. A randomised controlled trial of oral misoprostol vs injection methylergometrine for prevention of post partum hemorrhage. Int j Reprod Contracept Obstet Gynecol. 2013;2(3):296-304. [DOI:10.5455/2320-1770.ijrcog20130908]
20. Rajaei M, Karimi S, Shahboodaghi Z, Mahboobi H, Khorgoei T, Rajaei F. Safety and Efficacy of Misoprostol versus Oxytocin for the Prevention of Postpartum Hemorrhage. J Pregnancy. 2014;2014:713879. [DOI:10.1155/2014/713879] [PMID] [PMCID]
21. Abd El Aziz MA, Iraqi A, Abedi P, Jahanfar S. The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review. Syst Rev. 2018;7:1-8. [DOI:10.1186/s13643-018-0832-4] [PMID] [PMCID]
22. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003;29(2):125-30. [DOI:10.1055/s-2003-38897] [PMID]
23. Ducloy-Bouthors A, Broisin F, Keita H, Fontaine S, Depret S, Legoeff F, et al. Tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2010;14(1):P370. [DOI:10.1186/cc8602] [PMCID]
24. Simonazzi G, Bisulli M, Saccone G, Moro E, Marshall A, Berghella V. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand. 2016;95(1):28-37. [DOI:10.1111/aogs.12798] [PMID]
25. Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, Akintan A, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-16. [DOI:10.1016/S0140-6736(17)30638-4] [PMID]
26. Othman ER, Fayez MF, El Aal DEMA, El-Dine Mohamed HS, Abbas AM, Ali MK. Sublingual misoprostol versus intravenous oxytocin in reducing bleeding during and after cesarean delivery: A randomized clinical trial. Taiwan J Obstet Gynecol. 2016;55(6):791-5. [DOI:10.1016/j.tjog.2016.02.019] [PMID]
27. Li B, Miners A, Shakur H, Roberts I. Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial. Lancet Glob Health. 2018;6(2):e222-e8. [DOI:10.1016/S2214-109X(17)30467-9] [PMID]
28. Cordovani D, Balki M, Farine D, Seaward G, Carvalho JC. Carbetocin at elective Cesarean delivery: a randomized controlled trial to determine the effective dose. Can J Anaesth. 2012;59(8):751-7. [DOI:10.1007/s12630-012-9728-2] [PMID]
29. Ali AE-NAE -G, Nasr A, Ahmed H, et al. Carbetocin versus Oxytocin and Misoprostol in prevention of atonic post-partum hemorrhage in high risk patients planed for cesarean delivery. Int J Reprod Contracept Obstet Gynecol. 2017;7(1):10. [DOI:10.18203/2320-1770.ijrcog20175824]
30. Elgafor el Sharkwy IA. Carbetocin versus sublingual misoprostol plus oxytocin infusion for prevention of postpartum hemorrhage at cesarean section in patients with risk factors: a randomized, open trail study. Arch Gynecol Obstet. 2013;288(6):1231-6. [DOI:10.1007/s00404-013-2896-7] [PMID]
31. Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012(2):Cd005457. [DOI:10.1002/14651858.CD005457.pub4]
32. Saoud F, Stone A, Nutter A, Hankins GD, Saade GR, Saad AF. Validation of a new method to assess estimated blood loss in the obstetric population undergoing cesarean delivery. Am J Obstet Gynecol. 2019;221(3):267.e1-.e6. [DOI:10.1016/j.ajog.2019.06.022] [PMID]